Skip to main content
. Author manuscript; available in PMC: 2014 Nov 1.
Published in final edited form as: J Acquir Immune Defic Syndr. 2013 Nov 1;64(3):279–283. doi: 10.1097/qai.0b013e3182a97c39

TABLE 2.

Comparisons of Changes in Vascular, Metabolic, Inflammatory, Bone, and Renal Markers at Week 8 and Week 24

Laboratory Marker Continuation Group
Switch Group
Entry 8 Week Change 24 Week Change Entry 8 Week Change 24 Week Change
Vascular Markers
Flow-mediated dilation, % 3.82 (2.71) −0.41 (2.15) −0.67 (3.35) 3.09 (2.36) 1.17 (4.20) −0.10 (3.26)
Nitroglycerin-mediated dilation, %* 17.46 (9.08) 6.88 (9.42) −0.15 (8.55) 17.85 (8.46) −3.02 (6.43) −4.77 (8.95)
Metabolic Markers
HOMA-IR 1.75 (1.31) −0.04 (1.09) 0.58 (1.18) 1.67 (0.94) 0.17 (1.48) 0.60 (1.42)
Serum total cholesterol, mg/dL* 156.87 (32.93) 4.00 (16.86) 1.08 (9.88) 154.07 (36.67) −12.2 (16.95) −12.64 (19.61)
Serum HDL-C, mg/dL 42.27 (10.16) 0.85 (6.62) 0.15 (6.09) 39.33 (11.64) 0.13 (6.48) 0.29 (6.06)
Serum LDL-C, mg/dL* 89.39 (28.93) 6.08 (16.01) −2.23 (15.13) 90.61 (37.78) −8.58 (17.14) −8.65 (18.24)
Serum triglycerides, mg/dL 125 (64) −13(36) 16 (98) 120 (77) −19 (66) −22 (25)
Immunologic/inflammatory Markers
Serum hsCRP, mg/L 2.55 (2.45) 0.99 (6.13) −0.66 (2.07) 3.93 (3.95) −0.84 (2.70) −2.16 (2.20)
Serum IL-6, pg/mL 1.95 (1.42) −0.34 (1.32) −0.62 (1.10) 1.47 (1.66) 0.24 (1.32) −0.10 (0.88)
sCD14, ng/mL* 2441.15 (378.02) −173.28 (321.51) −112.54 (421.26) 2443.2 (283.94) −412.16 (288.84) −458.14 (319.03)
sCD163, ng/mL 575.80 (252.64) −28.96 (60.04) −32.26 (64.18) 577.21 (183.58) 15.24 (90.31) 32.00 (63.57)
Bone Homeostasis Markers
Serum alkaline phosphatase, mg/dL 84.00 (23.15) −7.58 (9.85) −4.92 (8.2) 78.47 (15.25) −7.07 (7.47) −12.46 (9.44)
Serum parathyroid hormone, pg/mL 62.41 (18.39) 0.19 (19.04) 11.45 (39.73) 56.51 (27.70) −5.76 (22.42) −10.08 (25.64)
Serum 25(OH)vitamin D, ng/mL 18.35 (20.31) −1.01 (6.70) −0.58 (9.95) 13.70 (12.86) 5.28 (9.46) 4.50 (12.52)
Renal Function/Injury Markers
Serum creatinine, mg/dL*§ 0.91 (0.23) −0.01 (0.06) −0.02 (0.10) 0.93 (0.16) 0.06 (0.08) 0.08 (0.08)
Serum cystatin C, mg/L§ 0.80 (0.14) −0.06 (0.07) −0.03 (0.06) 0.75 (0.11) 0.07 (0.09) 0.07 (0.1)
Creatinine clearance, mL/min§ 129.64 (41.61) −2.00 (18.78) 12.25 (23.29) 130.93 (39.88) −7.36 (14.37) −11.69 (12.66)
Estimated GFR (2009 CKD-EPI), mL/min/1.732 110.55 (23.73) 0.51 (4.71) 0.74 (9.40) 111.15 (20.89) −4.77 (9.80) −8.67 (8.78)
Estimated GFR (2012 CKD-EPI Cystatin), mL/min/1.732§ 110.40 (17.13) 6.86 (11.54) 3.06 (8.07) 115.79 (12.11) −8.43 (11.26) −8.50 (11.04)
Estimated GFR (2012 CKD-EPI Cystatin-Creatinine), mL/min/1.732§ 100.19 (20.38) 5.24 (7.15) 2.72 (6.48) 102.7 (16.78) −7.09 (9.22) −8.22 (6.70)
Urine albumin/creatinine, mg/g 7.32 (7.39) 0.86 (8.13) −1.57 (2.90) 4.84 (3.98) −1.51 (2.26) 11.99 (44.84)
Urine protein/creatinine, g/g 0.12 (0.07) −0.01 (0.02) −0.01 (0.03) 0.08 (0.05) −0.01 (0.02) 0.01 (0.04)

Data presented as mean (standard deviation)

HOMA-IR, homeostasis model assessment-insulin resistance; HDL-C, high density lipoprotein-cholesterol; LDL-C, low density lipoprotein-cholesterol; hsCRP, high sensitivity C-reactive protein; IL-6, interleukin-6; sCD14 and 163, soluble cluster of differentiation 14 and 163; GFR, glomerular filtration rate

*

P<0.05 for differences between groups in the change from Entry to Week 8

P<0.01 for differences between groups in the change from Entry to Week 8

P<0.05 for differences between groups in the change from Entry to Week 24

§

P<0.01 for differences between groups in the change from Entry to Week 24